Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chiemeka Onyima

Anesthesiology Washington, DC Medical Doctor

NPI 1215460076 CMS profile 9614426

2150 Pennsylvania Ave Nw, Washington, DC 20037

Open in the dashboard

General payments

$2,570

44 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chiemeka Onyima of Washington, DC is reported in the CMS Open Payments database as having received $2,570 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,067 19
2024 General $368 7
2023 General $198 4
2022 General $395 4
2021 General $543 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chiemeka Onyima
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Chiemeka Onyima were reported at $1,067. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Chiemeka Onyima Anesthesiology median Middle half National median
2019 $0 $72 $23–$151 $163
2020 $0 $36 $17–$120 $114
2021 $543 $49 $21–$135 $132
2022 $395 $52 $22–$144 $149
2023 $198 $53 $23–$143 $160
2024 $368 $55 $25–$150 $164
2025 $1,067 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $680 18 payments
  2. Curonix LLC $524 4 payments
  3. Nevro Corp. $403 5 payments
  4. Globus Medical, Inc. $378 5 payments
  5. Abbott Laboratories $160 2 payments
  6. Avanos Medical $133 1 payment
  7. Boston Scientific Corporation $117 2 payments
  8. Heron Therapeutics, Inc. $69 1 payment
  9. Pfizer Inc. $33 2 payments
  10. Almatica Pharma LLC $31 2 payments
  11. Other $41 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,872 39 payments
  2. Travel and Lodging $698 5 payments
Products named General payments · program years 2021–2025
  1. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $524 4 payments
  2. INTELLIS ADAPTIVESTIM $431 9 payments
  3. Senza Spinal Cord Stimulator $378 5 payments
  4. Omnia $220 2 payments
  5. Senza Spinal Cord Stimulator $183 3 payments
  6. SYNCHROMED $161 1 payment
  7. GENERATOR $133 1 payment
  8. Proclaim IPG $128 1 payment
  9. General - Pain Management $89 1 payment
  10. Zynrelef $69 1 payment
  11. Other $221 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

2,358

Median for Anesthesiology: 322

Drug cost

$35,256

Median for Anesthesiology: $8,738

Branded share of claims

12.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 692 $8,539
Lidocaine Generic 195 $5,528
Pregabalin Generic 243 $4,380
Duloxetine Hcl Generic 140 $2,966
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 136 $2,404
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 96 $1,540
Tizanidine Hcl Generic 100 $1,383
Cyclobenzaprine Hcl Generic 92 $1,148
Tramadol Hcl Er Tramadol Hcl Brand 16 $1,091
Oxycodone Hcl Generic 62 $946

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$119,795

Of which drugs: $1,647

Medicare patients

405

Average age 71

Services billed

3,690

245 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 44%
Depression 44%
Ischemic heart disease 37%
COPD 33%
Chronic kidney disease 31%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 1,340 $131
Injection, ketorolac tromethamine, per 15 mg J1885 Office 15 54 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record